File: '\\swfile\EmailIn\20241224 132543 Attachment 2024_12_24 ENBI NR proceeding on NBPP financing Upsize.docx'

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

Entheon Biomedical Announces Private Placement Financing upsize to $500,000

VANCOUVER, BC, December 24, 2024 - Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") announces an increase on a private placement financing of up to 5,000,000 Units (the "Units") at a price of CDN$0.10 per Unit for gross proceeds of up to CDN$500,000 (the "Placement") referenced to the news release date December 2, 2024.

Each Unit will consist of one common share in the capital of the Company (a "Share") and one transferable share purchase warrant (a "Warrant"). Each Warrant will be exercisable to acquire one additional Share at an exercise price of CDN$0.15 per Share for a period of 24 months from the date of issuance.

The sale of the Shares and warrant shares will result in the issuance of more than 100% of the number of issued and outstanding Shares of the Company immediately prior to the closing of the Offering. The Canadian Securities Exchange (the "CSE") approved the Company's reliance on an exemption from the shareholder approval requirements in Section 4.6(2)(b) of CSE Policy 4 - Corporate Governance, Security Holder Approvals and Miscellaneous Provisions on the basis that the Company was in serious financial difficulty and that the Company's independent directors determined that the Offering was in the best interests of the Company and that it was not feasible to obtain securityholder approval in a timely manner. No Related Persons (as that term is defined in the policies of the CSE) participated in the Offering. Accordingly, the Company did not hold a vote of its shareholders to approve the sale of the Units under the Offering.

The Company intends to use the proceeds from the Placement towards general working capital purposes. All securities issued under the Placement will be subject to a four-month and one-day hold period and the Company may pay finder's fees in accordance with the policies of the Canadian Securities Exchange.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

On Behalf of the Board of Directors,

Timothy Ko, CEO, President and Director

For more information, please contact the Company at:

Entheon Biomedical Corp.

Timothy Ko, CEO

timothy@entheonbiomedical.com

https://entheonbiomedical.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws. Forward-Looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include the future performance of the Company. Forward-Looking statements are based on the opinions and estimates at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedarplus.ca.